^
Association details:
| Biomarker: | TYMS overexpression + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Published date:
09/01/2020
Excerpt:
The MONALEESASIA study enrolled 88 Asian patients with HR+, HER2− advanced (locoregionally recurrent or metastatic) breast cancer...ribociclib in combination with letrozole….In good responders, higher expression levels of MAP3K8 and genes regulated by E2F were observed compared with poor responders. Conversely, in poor responders higher expression levels of TYMS, FGFR1, and cell cycle‐related genes were observed compared with good responders.
Secondary therapy:
letrozole
DOI:
10.1111/cas.14554
Trial ID:
